Treatment Paradigms and DMT Choices

Volume 3, Issue 9

Treatment Paradigms and DMT Choices

In this issue:

What factors should most influence the choice of a disease-modifying therapy for a patient with diagnosed RRMS? Which treatment paradigm is likely to provide the most benefit? How much weight should each person’s demographic, clinical, and paraclinical characteristics be given in the decision-making process? What about the aggressiveness of the disease and potential long-term disability outcomes? And how much say should the patient have in determining which treatment will best meet their needs?

Those are some of the questions addressed by Drs. Scott Newsome, Olwen Murphy, and Anne Damian from the Johns Hopkins University and Dr. Yujie Wang from the University of Washington in their expert analysis of the recent literature in this issue of eMultipleSclerosis Review.

Learning objectives:

Describe the available treatment paradigms (escalation approach, early highly effective therapy approach, and personalized approach incorporating individual prognostic factors) for people with MS.
Compare the potential risk profiles that may be associated with specific highly effective therapies vs modestly effective therapies.

Authors:

Scott Newsome, DO, MSCS, FAAN, FANA

Associate Professor of Neurology 
Johns Hopkins Hospital 
Baltimore, MD

Yujie Wang, MD

Acting Assistant Professor of Neurology

University of Washington

Seattle, WA
Adjunct Assistant Professor of Neurology

Johns Hopkins University

Baltimore, MD

Anne Damian Yacoub, MD

Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

Olwen C. Murphy, MB, BCH, MRCP

Neurology fellow
Johns Hopkins University School of Medicine
Baltimore, MD

Guest Faculty Disclosures

Dr. Newsome has disclosed that he has received consulting fees from Biogen Idec, Genentech, Celgene, and EMD Serono, has served as a clinical adjudication committee member for medDay Pharmaceuticals, and as a principal investigator for Biogen Idec and Genentech, Inc.

The other authors have indicated that they have no financial interests or relationships with a commercial entity. 

Unlabeled/Unapproved Uses

The authors have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products. 

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures:

The other authors have indicated that they have no financial interests or relationships with a commercial entity. 

Unlabeled/Unapproved Uses:

The authors have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products. 

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 3, 2021
Expiration date: March 2, 2023

Start Issue